Core Insights - Beckman Coulter Life Sciences has achieved a significant milestone in localizing its production in China with the launch of the Optima XPN-100 ultracentrifuge, marking the establishment of complete local production and quality validation capabilities for ultracentrifuges in the country [1][3] Group 1: Production and Quality Management - The local production of the Optima XPN-100 signifies the formation of an engineering and quality management system that supports high-end centrifuge manufacturing in China, laying a sustainable foundation for future localization of high-end instruments [3] - The Suzhou factory has developed a comprehensive process system that includes quality management, supply chain management, environmental testing, assembly processes, and performance validation, ensuring stable supply for the production of ultracentrifuges [5][8] Group 2: Product Features and Applications - The Optima XPN-100 is a flagship ultracentrifuge with a maximum speed of 100,000 rpm and a maximum centrifugal force of 802,000 x g, featuring revolutionary innovations such as intelligent temperature control and dynamic inertia detection, providing efficient and high-purity separation for samples like nucleic acids, proteins, and viral particles [4][11] - This ultracentrifuge plays an irreplaceable role in significant scientific breakthroughs, including the Human Genome Project, mRNA vaccine development, CAR-T cell therapy, and AAV gene vector purification [7] Group 3: Commitment to Local Market - The local production of the Optima XPN-100 is a fulfillment of the company's long-term commitment to Chinese customers, significantly shortening delivery times and enhancing installation, debugging, and after-sales service response speeds [9] - The company plans to produce more models of high-speed centrifuges and cell counters at the Suzhou factory, continuously enhancing local R&D, manufacturing, and service capabilities to support the development of life sciences research in China [9]
超速离心机本土化量产落地,贝克曼库尔特生命科学在华布局再进一步